US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Apimeds Pharmaceutical U.S, Inc.

1.91

+0.280017.18%

Post-market: 1.86-0.0500-2.62%18:22 EDT

Volume:129.80K

Turnover:232.78K

Market Cap:24.02M

PE:-4.66

High:1.91

Open:1.64

Low:1.62

Close:1.63

52wk High:4.03

52wk Low:0.9510

Shares:12.58M

Float Shares:337.50K

Volume Ratio:0.83

T/O Rate:38.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4100

EPS(LYR):-0.1759

ROE:-144.99%

ROA:-69.29%

PB:2.94

PE(LYR):-10.86

Loading ...

Overview Company News Filings

Apimeds Pharmaceuticals Removes Erik Emerson from Board

BRIEF-E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave

Apimeds Merges with MindWave to Integrate Biotech and AI Treasury Platforms

E.f. Hutton Advises on Strategic Merger Between Apimeds and Mindwave, Aligning Biotech Growth With AI-Enabled Financial Innovation

THOMSON REUTERS

Apimeds Pharmaceuticals and Mindwave Innovations Announce Closing of $100Mm Pipe Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy

THOMSON REUTERS

Apimeds Pharmaceuticals Directors Vin Menon and Amir Dossal Resign

Apimeds Pharmaceuticals US Inc. Issues Correction to Merger Agreement and Certificate of Designation

Amex Halt News Pending Lst 2.900000

THOMSON REUTERS

BRIEF-Apimeds And Mindwave Announce Merger, Integrating Biotech Growth With AI

Apimeds Pharmaceuticals Merges With MindWave Innovations in $100M Deal

Apimeds and Mindwave Announce Merger, Integrating Biotech Growth With AI-Driven Digital Treasury Yield Generation Backed by $100M Pipe

THOMSON REUTERS

Apimeds Pharmaceuticals Amends CEO Employment Agreement

Apimeds Pharmaceuticals US Inc. Raises CEO Erik Emerson’s Salary to $500,000 and Updates Severance Terms

Apimeds Pharmaceuticals Amends Bylaws to Allow Shareholder Action by Written Consent

Apimeds Pharmaceuticals expands AI Futures Lab program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/APUS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","market":"US","secType":"STK","nameCN":"Apimeds Pharmaceutical  U.S, Inc.","latestPrice":1.91,"timestamp":1774641600000,"preClose":1.63,"halted":0,"volume":129795,"hourTrading":{"tag":"盘后","latestPrice":1.86,"preClose":1.91,"latestTime":"18:22 EDT","volume":262,"amount":488.7077,"timestamp":1774650133459,"change":-0.05,"changeRate":-0.026178,"amplitude":0.026178},"delay":0,"changeRate":0.1717791411042945,"floatShares":337500,"shares":12575983,"eps":-0.41,"marketStatus":"Closed","change":0.28,"latestTime":"03-27 16:00:00 EDT","open":1.64,"high":1.91,"low":1.62,"amount":232779.9731235,"amplitude":0.177914,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"adr":0,"listingDate":1746763200000,"exchange":"AMEX","adjPreClose":1.63,"postHourTrading":{"tag":"盘后","latestPrice":1.86,"preClose":1.91,"latestTime":"18:22 EDT","volume":262,"amount":488.7077,"timestamp":1774650133459,"change":-0.05,"changeRate":-0.026178,"amplitude":0.026178},"volumeRatio":0.828013},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","floatShares":337500,"roa":"-69.29%","roe":"-144.99%","lyrEps":-0.175862,"volumeRatio":0.828013,"shares":12575983,"dividePrice":0,"high":1.91,"amplitude":0.177914,"preClose":1.63,"low":1.62,"week52Low":0.951,"pbRate":"2.94","week52High":4.031,"institutionHeld":0,"latestPrice":1.91,"eps":-0.41,"divideRate":0,"volume":129795,"delay":0,"ttmEps":-0.41,"open":1.64,"prevYearClose":1.64,"prevWeekClose":2.06,"prevMonthClose":1.36,"prevQuarterClose":1.64,"fiveDayClose":2.06,"twentyDayClose":1.36,"sixtyDayClose":1.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APUS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APUS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APUS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APUS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APUS","date":"2025-12-01","current":-4.658537,"percent":0.642384,"low":-37.866629,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"high":-4.754876,"avg":-11.953693,"sd":7.073766,"marketCap":36470350},"quantilePoints":[{"date":"2025-02-21","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-02-28","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-03-05","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-05-09","current":-18.309826,"twenty":-34.716764,"median":-34.716764,"eighty":-33.299512,"marketCap":25450475},{"date":"2025-05-16","current":-14.148502,"twenty":-34.716764,"median":-34.008138,"eighty":-15.063993,"marketCap":19666276},{"date":"2025-05-23","current":-14.074662,"twenty":-34.716764,"median":-18.309826,"eighty":-14.306662,"marketCap":21054484},{"date":"2025-05-30","current":-13.387434,"twenty":-34.716764,"median":-15.063993,"eighty":-14.061031,"marketCap":20026450},{"date":"2025-06-06","current":-14.702962,"twenty":-34.716764,"median":-14.800251,"eighty":-13.996937,"marketCap":21994367},{"date":"2025-06-13","current":-14.314495,"twenty":-34.716764,"median":-14.564634,"eighty":-14.061031,"marketCap":21413253},{"date":"2025-06-20","current":-13.774354,"twenty":-33.866413,"median":-14.548195,"eighty":-14.0474,"marketCap":20605249},{"date":"2025-06-27","current":-13.296895,"twenty":-33.299512,"median":-14.356338,"eighty":-13.867215,"marketCap":19891011},{"date":"2025-07-03","current":-13.774354,"twenty":-27.303638,"median":-14.27266,"eighty":-13.727614,"marketCap":20605249},{"date":"2025-07-11","current":-14.006506,"twenty":-17.177946,"median":-14.161274,"eighty":-13.727614,"marketCap":20952529},{"date":"2025-07-18","current":-13.851738,"twenty":-15.354982,"median":-14.154888,"eighty":-13.727614,"marketCap":20721009},{"date":"2025-07-25","current":-16.173259,"twenty":-16.219689,"median":-14.161274,"eighty":-13.727614,"marketCap":24193804},{"date":"2025-08-01","current":-13.464818,"twenty":-16.219689,"median":-14.199966,"eighty":-13.727614,"marketCap":20142210},{"date":"2025-08-08","current":-12.14929,"twenty":-16.049445,"median":-14.148502,"eighty":-13.573156,"marketCap":18174293},{"date":"2025-08-15","current":-12.265366,"twenty":-15.710284,"median":-14.056061,"eighty":-13.418388,"marketCap":18347933},{"date":"2025-08-22","current":-7.697345,"twenty":-15.447843,"median":-14.006506,"eighty":-13.015991,"marketCap":28547481},{"date":"2025-08-29","current":-6.307075,"twenty":-15.306558,"median":-13.929122,"eighty":-12.721932,"marketCap":23391328},{"date":"2025-09-05","current":-6.307075,"twenty":-15.146611,"median":-13.929122,"eighty":-12.474303,"marketCap":23391328},{"date":"2025-09-12","current":-6.578348,"twenty":-15.038217,"median":-13.851738,"eighty":-12.234412,"marketCap":24397407},{"date":"2025-09-19","current":-6.205348,"twenty":-14.9276,"median":-13.774354,"eighty":-7.507455,"marketCap":23014048},{"date":"2025-09-26","current":-6.049367,"twenty":-14.889578,"median":-13.773581,"eighty":-6.849619,"marketCap":22435553},{"date":"2025-10-03","current":-5.832349,"twenty":-14.826776,"median":-13.69697,"eighty":-6.578348,"marketCap":21630690},{"date":"2025-10-10","current":-6.307075,"twenty":-14.675296,"median":-13.542202,"eighty":-6.472551,"marketCap":23391328},{"date":"2025-10-17","current":-6.239257,"twenty":-14.561346,"median":-13.50351,"eighty":-6.415584,"marketCap":23139808},{"date":"2025-10-24","current":-5.879822,"twenty":-14.548195,"median":-13.387434,"eighty":-6.358617,"marketCap":21806754},{"date":"2025-10-31","current":-6.917438,"twenty":-14.538909,"median":-13.039206,"eighty":-6.374893,"marketCap":25655005},{"date":"2025-11-07","current":-8.524725,"twenty":-14.481047,"median":-12.845746,"eighty":-6.381675,"marketCap":31616021},{"date":"2025-11-14","current":-9.460613,"twenty":-14.381444,"median":-12.652286,"eighty":-6.415584,"marketCap":35086992},{"date":"2025-11-21","current":-5.852155,"twenty":-14.312928,"median":-12.458826,"eighty":-6.415584,"marketCap":30182359},{"date":"2025-11-28","current":-7.071353,"twenty":-14.306662,"median":-12.304058,"eighty":-6.374893,"marketCap":36470350},{"date":"2025-12-01","current":-7.071353,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"marketCap":36470350}],"updateTime":1774641609833},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APUS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2600935340","title":"Apimeds Pharmaceuticals Removes Erik Emerson from Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2600935340","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600935340?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:31","pubTimestamp":1767389488,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. has announced the removal of Erik Emerson from its board of directors, effective December 30, 2025. The current board members are Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub, PhD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL7l96Fx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"gpt_icon":0},{"id":"2592918653","title":"BRIEF-E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918653","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918653?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:27","pubTimestamp":1765978046,"startTime":"0","endTime":"0","summary":"BRIEF-E.F. Hutton Advises On Strategic Merger Between Apimeds And MindwaveDec 17 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A:E.F. HUTTON ADVISES ON STRATEGIC MERGER BETWEEN APIMEDS AND MINDWAVE,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA1QK2XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2592990924","title":"Apimeds Merges with MindWave to Integrate Biotech and AI Treasury Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990924","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990924?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976501,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. and MindWave Innovations Inc. have completed a merger that combines Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-powered digital treasury infrastructure. The integration is supported by a $100 million PIPE commitment, enabling the newly formed entity to accelerate its development pipeline and enhance capital management through MindWave's AI-driven treasury engine. E.F. Hutton served as the exclusive M&A advisor and placement agent, coordinating transaction terms and the capital raise to support the combined company's strategic growth across biotech and digital asset management. This merger positions the business for long-term scalability by uniting biotech innovation with AI-based financial optimization. The announcement was made by E.F. Hutton.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLzt91w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","NDAQ","BK4139","SG9999014013.SGD","LU2210150020.SGD","SG9999014039.USD","APUS","BK4588","BK4585"],"gpt_icon":0},{"id":"2592990671","title":"E.f. Hutton Advises on Strategic Merger Between Apimeds and Mindwave, Aligning Biotech Growth With AI-Enabled Financial Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990671?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA1QK2XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"gpt_icon":0},{"id":"2590358975","title":"Apimeds Pharmaceuticals and Mindwave Innovations Announce Closing of $100Mm Pipe Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590358975?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:58","pubTimestamp":1765378680,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA5XPBHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2590538715","title":"Apimeds Pharmaceuticals Directors Vin Menon and Amir Dossal Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538715","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590538715?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:20","pubTimestamp":1765376437,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. announced that Dr. Vin Menon and Amir A. Dossal have resigned from the company's Board of Directors, effective December 5, 2025. The company stated that the resignations were not due to any disagreements regarding company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLbp6lf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2590387135","title":"Apimeds Pharmaceuticals US Inc. Issues Correction to Merger Agreement and Certificate of Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590387135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590387135?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:19","pubTimestamp":1765376343,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. has issued an amendment to its previously filed Form 8-K, correcting clerical errors in the Agreement and Plan of Merger and the Certificate of Designation. The company stated that these corrections were solely to reflect the accurate intent of the parties, with no other material terms or disclosures affected. The corrected documents have been filed as exhibits to the amendment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLdMS8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2588775134","title":"Amex Halt  News Pending Lst 2.900000","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775134","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588775134?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:35","pubTimestamp":1764599740,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nAQN2LBKCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2588759517","title":"BRIEF-Apimeds And Mindwave Announce Merger, Integrating Biotech Growth With AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2588759517","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588759517?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:27","pubTimestamp":1764599229,"startTime":"0","endTime":"0","summary":"BRIEF-Apimeds And Mindwave Announce Merger, Integrating Biotech Growth With AIDec 1 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A:APIMEDS AND MINDWAVE ANNOUNCE MERGER, INTEGRATING BIOTECH GROWTH W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9RZJD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2588775327","title":"Apimeds Pharmaceuticals Merges With MindWave Innovations in $100M Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775327","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588775327?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:25","pubTimestamp":1764599114,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. and MindWave Innovations Inc. have signed a merger agreement to combine their businesses, creating an enterprise that spans advanced biotechnology and institutional digital-asset treasury solutions. The merged entity will integrate Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury and digital asset yield generation platform. The transaction is supported by a private investment of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. Following the merger, Apimeds' assets and liabilities will be transferred to a wholly owned subsidiary, where its core business will continue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1yf3PQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"gpt_icon":0},{"id":"2588775558","title":"Apimeds and Mindwave Announce Merger, Integrating Biotech Growth With AI-Driven Digital Treasury Yield Generation Backed by $100M Pipe","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588775558?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:25","pubTimestamp":1764599100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9RZJD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2584496908","title":"Apimeds Pharmaceuticals Amends CEO Employment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584496908","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584496908?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:16","pubTimestamp":1763504170,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an update. On November 13, 2025, Apimeds Pharmaceuticals US, Inc. amended its Executive E...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-amends-ceo-employment-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-amends-ceo-employment-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","BK4139"],"gpt_icon":0},{"id":"2584969304","title":"Apimeds Pharmaceuticals US Inc. Raises CEO Erik Emerson’s Salary to $500,000 and Updates Severance Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969304","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969304?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:58","pubTimestamp":1763503099,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. has amended the employment agreement for its Chief Executive Officer, Erik Emerson, effective November 13, 2025. Under the new terms, Emerson's annual base salary increases to $500,000. If terminated without cause, Emerson will be entitled to a severance payment equal to 24 months of base salary and benefits, along with immediate vesting of all unvested equity, contingent upon signing a release of claims. If terminated for cause or if he resigns without good reason, any unvested equity will be forfeited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6T82Z9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2576773867","title":"Apimeds Pharmaceuticals Amends Bylaws to Allow Shareholder Action by Written Consent","url":"https://stock-news.laohu8.com/highlight/detail?id=2576773867","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576773867?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:16","pubTimestamp":1760645771,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US Inc. announced that its board of directors has amended the company's bylaws to allow shareholder action by written consent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL2dTz31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"gpt_icon":0},{"id":"2575298038","title":"Apimeds Pharmaceuticals expands AI Futures Lab program","url":"https://stock-news.laohu8.com/highlight/detail?id=2575298038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575298038?lang=en_us&edition=fundamental","pubTime":"2025-10-14 17:30","pubTimestamp":1760434218,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals (APUS) announced the expansion of the Apimeds AI Futures Lab program through a new collaboration with the University of Ore...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apimeds-pharmaceuticals-expands-ai-futures-lab-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apimeds-pharmaceuticals-expands-ai-futures-lab-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","BK4528","BK4023","BK4587","BK4588","BK4585","BK4551","BK4543","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}